Work

Phase 1 Clinical Trial of Losmapimod in Facioscapulohumeral Muscular Dystrophy (FSHD): Safety, Tolerability, and Target Engagement (1557)

Year: 2020

Type: article

Source: Neurology

DOI: 10.1212/wnl.94.15_supplement.1557

Authors: Michelle Mellion, Lucienne Ronco, Lorin Thompson, Michelle Hage, Sander Brooks, Emilie van Brummelen, Lisa Pagan, Umesh Badrising, Shane Raines, William Tracewell, Baziel van Engelen, Geert-Jan Groeneveld, Diego Cadavid

Institutions: Fulcrum Therapeutics (United States), Centre for Human Drug Research, Leiden University Medical Center, Radboud University Medical Center

Language: English

Topic: Muscle Physiology and Disorders

Subfield: Molecular Biology

Field: Biochemistry, Genetics and Molecular Biology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W3043311202

FWCI: 0.243

Cites:

Cited by: 3

Related to: 10